ScripThird Harmonic Bio and Q32 Bio are not in imminent danger of running out of cash, but both companies recently took a look at early data for their lead drug candidates and decided to significantly cut
ScripPierre Fabre is hoping that it can succeed where a host of companies have failed in getting a treatment onto the market for X-linked hypohidrotic ectodermal dysplasia (XLHED), a rare pediatric geneti
ScripReturns from newly public biotechnology companies are far below gains from US biotech stocks in general, but that's not stopping drug developers from filing for initial public offerings, including fiv
In VivoIN VITRO DIAGNOSTICS Alliances Angle PLC Qiagen NV Angle PLC and Qiagen NV will co-promote each other’s liquid biopsy solutions for cancer detection. (Sep.) To the deal Angle contributes its